Patrick Wood

is there any structural change that happened recently or in the past that would preclude you from sort of hitting that normalized mid-single-digit growth rate

Is there not a temptation just to get off to the RMT even more aggressive in returning capital to shareholders, just given where the yield on the stock is

is it the right framework? Is there any reason we would be wrong to think that RemainCo should be stable in that kind of mid-single-digit plus kind of a range

my question is kind of to what extent you build muscle tissue in that skill set internally with the employees

if you end up going down the sale route and with a cash injection, are there any areas that you particularly feel you'd like to bulk up on

question around potential tariffs, supply chain impacts. Do you benefit from onshoring relative to any potential paths to go in

how much is that going to help things like seismic in the IVL side and TCAR building out that force in a larger way?

What was it that kind of made you feel like now is the time? I know you guys have been following them closely for a while

in terms of Empower and the approval of that in the second half, how are you thinking of the outlook for that division

I'm super curious how you think midterm, you know, how big that business could be

how do you guys know about the Clarity versus MyDay sort of dynamic? Was that feedback that came from, like, chatting to optometrists, or was that coming from the Salesforce?

US, target penetration, I would love to like, can you remind us kind of where you think we are up to today in target penetration for those who are asthmatic.

how are you thinking long term about what the average wet time will do

where are we at in terms of, you know, account sort of breadth versus depth

there's been a lot of sort of shuffle around with the FDA overall and people fired, rehired

your MUSE platform has like a 50% market share, if I'm right, on the ECG side of things

one of your peers has [ vice ] fund with the FDA. I think we all [indiscernible] through this before

Is the solution here in your mind, like a lower-end form factor? Or do we stick with refurbished systems?

how much do you guys think you need to continue to bend the cost curve down for INA to make it work in the ASC?

if you think of the efficiencies from your install-based entities, so over time, as you're placing more and more systems and in individual areas

How are we thinking about capital allocation and M&A? There's a lot of other companies doing very large deals in the space. I'm just trying to work out directionally, do you guys feel still more th...

how are those reflective relative to the NCD? Like, are there restrictions being put on? You know, what is the sort of tone of the conversation

would it be fair to assume that the base algorithm, call it, mid-single-digit growth, and then high singles on the bottom line, that that's a fair assumption moving into fiscal '26

Given the focus on tuck-in M&A, I'm just curious, the kind of assets you're most interested on that side

Is this a multiple visit kind of thing that competes them to switch over? Or is it happening pretty quickly

I'd love to sort of get a sense for midterm, your view of sustainability there. And how much is a function of Omnipod 5

was this one that was kind of kicking around that you guys had initiated pretty early on? Or was this a function of tariffs

how are you feeling about that capital allocation? You mentioned bolt- on M&A, but like how much you feel you need to do that to buy into the kind of midterm growth range

is it a fair assumption on our end to assume that the general price mix trends that you've seen in the previous quarter was consistent here

is it fair to assume that while you're going to have 100 points of organic growth headwind on that side, that we should see something on the operating margin

a bit more of a commercial push in EMEA across some of your product lines on the sterilization side

CMS had two different proposals. That was obviously the PPE sort of onshoring, some of the API stuff on the drug side

on the modality side like X-ray, could you give us a sense of how that's contributed to growth

Healthcare on the service side also was very strong. What are you seeing there?

how the conversations with the customer has been around potentially like onshoring back to the U.S.

Is there a situation where they end up having to force sell themselves essentially to you guys or your peers

do you think there's any opportunity for the intensity of the legislative change around EO to loosen up a little bit

on the endoscopy side of the business. Just curious where you're seeing, you know, both in the demand for your scopes on the volume side

the yield litigation side of things. Do we have any update on that on upcoming news flow

have you heard from any of your customers around supply chain changes, tariffs coming in

what are the implications for that if any, with an endoscopy and everything else? Is your share in some of these categories high enough that it's like, hey, it's just a change of side of care

Is that still the case? Would you look at things like calcium management and other things that are sort of ancillary to that

I'd love if you could unpack a little bit more on the Endoscopy side of things. I know you talked about sports med and visualization

moving to a negative 100 basis points erosion in the 26 guide, inflation is kind of at the same spot

Was that at like the rep level? Was that at the divisional head level? Just any more details on how you're structuring the incentive plan

The numbers and the strength that you guys have seen there, do you know has that been predominantly on the coxa vara side? Or has that been more broad-based across Hip

how are you thinking A about the opportunity to push it through your distribution sales network both in the U.S. and OUS